Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Payables (2016 - 2025)

Historic Payables for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $24.0 million.

  • Adma Biologics' Payables rose 4994.38% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 4994.38%. This contributed to the annual value of $20.2 million for FY2024, which is 2911.24% up from last year.
  • As of Q3 2025, Adma Biologics' Payables stood at $24.0 million, which was up 4994.38% from $29.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Payables registered a high of $112.2 million during Q1 2021, and its lowest value of $6.2 million during Q2 2021.
  • Over the past 5 years, Adma Biologics' median Payables value was $15.7 million (recorded in 2023), while the average stood at $21.3 million.
  • Over the last 5 years, Adma Biologics' Payables had its largest YoY gain of 112541.44% in 2021, and its largest YoY loss of 8880.98% in 2021.
  • Adma Biologics' Payables (Quarter) stood at $12.4 million in 2021, then rose by 6.43% to $13.2 million in 2022, then increased by 18.38% to $15.7 million in 2023, then increased by 29.11% to $20.2 million in 2024, then rose by 18.8% to $24.0 million in 2025.
  • Its last three reported values are $24.0 million in Q3 2025, $29.8 million for Q2 2025, and $20.6 million during Q1 2025.